105 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
27 Feb 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
7:30am
in employee related costs related to hiring activities to support the launch of SYFOVRE, an increase in commercialization related activity
8-K
EX-1.1
msxuf
1 Nov 23
Entry into a Material Definitive Agreement
7:59am
424B5
gp777 ohqumfq
1 Nov 23
Prospectus supplement for primary offering
7:51am
8-K
EX-99.1
yi9t6ql
31 Jul 23
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
8:03am
8-K
EX-1.1
dqr35jsvtuur
24 Mar 22
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8:18pm
424B5
6cqy 367l
24 Mar 22
Prospectus supplement for primary offering
8:02pm
424B5
ouexy7cv zs0
23 Mar 22
Prospectus supplement for primary offering
5:14pm